Standard Biotools (LAB) EBIAT (2016 - 2025)
Standard Biotools (LAB) has disclosed EBIAT for 16 consecutive years, with $35.4 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 147.06% to $35.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$58.8 million through Dec 2025, up 66.37% year-over-year, with the annual reading at -$58.8 million for FY2025, 57.64% up from the prior year.
- EBIAT for Q4 2025 was $35.4 million at Standard Biotools, up from -$34.7 million in the prior quarter.
- The five-year high for EBIAT was $35.4 million in Q4 2025, with the low at -$76.3 million in Q1 2022.
- Average EBIAT over 5 years is -$28.9 million, with a median of -$21.9 million recorded in 2024.
- The sharpest move saw EBIAT plummeted 305.33% in 2022, then skyrocketed 147.06% in 2025.
- Over 5 years, EBIAT stood at -$13.8 million in 2021, then crashed by 50.58% to -$20.8 million in 2022, then rose by 5.13% to -$19.8 million in 2023, then crashed by 279.85% to -$75.1 million in 2024, then surged by 147.06% to $35.4 million in 2025.
- According to Business Quant data, EBIAT over the past three periods came in at $35.4 million, -$34.7 million, and -$33.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.